​

Crescent Biopharma Stock (NASDAQ:CBIO)

ForecastRevenueOwnershipFinancialsChart
Crescent Biopharma by TradingView

Previous Close

$16.76

52W Range

$8.72 - $27.41

50D Avg

$18.51

200D Avg

$14.60

Market Cap

$478.10M

Avg Vol (3M)

$319.62K

Beta

1.19

Div Yield

-

CBIO Company Profile

Crescent Biopharma, Inc. is a biotechnology firm dedicated to the research and development of novel cancer therapies. Its investigational portfolio notably includes CR-001, a proprietary bispecific antibody engineered to simultaneously target PD-1 and VEGF pathways for the treatment of solid tumors. The company's pipeline further comprises CR-002 and CR-003. Crescent Biopharma also maintains a strategic alliance with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., focusing on the joint advancement and commercialization of oncology therapeutics, encompassing innovative combination approaches. The company's operations are headquartered in Waltham, Massachusetts.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

41

IPO Date

Jan 10, 2014

Website

CBIO Performance

Revenue Breakdown

Revenue Breakdown by Product/Service

Product/ServiceDec 25Dec 24
Reportable Segment$10.84M-
Product-$105.80M

Fiscal year ends in Dec 25 | Currency in USD

CBIO Financial Summary

Dec 25Dec 24Dec 23
Revenue--$10.00K
Operating Income$-152.63M$-68.76M$-39.28M
Net Income$-149.94M$-71.47M$-36.90M
EBITDA$-152.63M-$-39.12M
Basic EPS$-12.82K$-0.59$-0.58
Diluted EPS$-12.82K$-0.59$-0.58

Fiscal year ends in Dec 25 | Currency in USD

Latest Earnings Call Transcripts

Q1 24May 06, 24 | 12:00 AM
Q4 23Mar 27, 24 | 8:30 AM
Q3 23Nov 03, 23 | 8:30 AM

Peer Comparison

TickerCompany
IMDXInsight Molecular Diagnostics Inc.
HINDVyome Holdings, Inc.
CCCCC4 Therapeutics, Inc.
HRTXHeron Therapeutics, Inc.
TNXPTonix Pharmaceuticals Holding Corp.
OABIOmniAb, Inc.
SGMOSangamo Therapeutics, Inc.
IPHAInnate Pharma S.A.
CGENCompugen Ltd.